Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932570 | 0.86 | MAPT (0.42) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL1115901 | 0.86 | MAPT (0.44) | MAPTMEN1KMT2ARXFP1TP53 | |
| SCHEMBL2931594 | 0.84 | RXFP1 (0.44) | MAPTMEN1KMT2ARXFP1TP53 | |
| SCHEMBL2925195 | 0.79 | NPC1 (0.40) | MAPTKMT2ATP53NPC1RAB9A | |
| SCHEMBL13989934 | 0.77 | MEN1 (0.45) | MAPTMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL2927954 | 0.75 | MAPT (0.39) | MAPTKMT2ATP53NPC1RAB9A | |
| SCHEMBL1115889 | 0.72 | MAPT (0.43) | MAPTMEN1KMT2ATP53NPC1 | |
| SCHEMBL1115893 | 0.72 | MAPT (0.42) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2924883 | 0.71 | MAPT (0.44) | MAPTMEN1KMT2ARXFP1NPC1 | |
| SCHEMBL2931417 | 0.71 | MAPT (0.39) | MAPTMEN1KMT2ATP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910314-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| EP-1910314-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009774-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306064-A1 | Benzimidazole Derivatives | PPARG, PPARD, BRD4 | MAPT 2716/4885MEN1 4765/4885KMT2A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.